[
  {
    "ts": null,
    "headline": "Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps",
    "summary": "On Saturday, Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis (PN), a chronic skin condition characterized by very itchy firm lumps. The data were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting. Also Read: Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opz",
    "url": "https://finnhub.io/api/news?id=6a351bdedcb5fe28f2e86a6b65bd581e7bb0f11a1a34cff2b3206e8e676dccff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741628291,
      "headline": "Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps",
      "id": 133193443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "On Saturday, Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis (PN), a chronic skin condition characterized by very itchy firm lumps. The data were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting. Also Read: Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opz",
      "url": "https://finnhub.io/api/news?id=6a351bdedcb5fe28f2e86a6b65bd581e7bb0f11a1a34cff2b3206e8e676dccff"
    }
  },
  {
    "ts": null,
    "headline": "INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies",
    "summary": "Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.",
    "url": "https://finnhub.io/api/news?id=73bba77e1475c127e73f2c65cdae781ba4556b68a6992dafbc6304ad06fa3064",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741618320,
      "headline": "INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies",
      "id": 133193444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.",
      "url": "https://finnhub.io/api/news?id=73bba77e1475c127e73f2c65cdae781ba4556b68a6992dafbc6304ad06fa3064"
    }
  },
  {
    "ts": null,
    "headline": "LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study",
    "summary": "Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.",
    "url": "https://finnhub.io/api/news?id=8d796703ef876c4a175dc0581da5116589cc25bd9a432c747e6ed66eec51c82a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741612380,
      "headline": "LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study",
      "id": 133193445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.",
      "url": "https://finnhub.io/api/news?id=8d796703ef876c4a175dc0581da5116589cc25bd9a432c747e6ed66eec51c82a"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Reports Inducement Grants under Nasdaq Listing Rule 5635(4)",
    "summary": "WILMINGTON - Incyte today announced that it granted restricted stock unit awards representing an aggregate of 13,351 shares of the Company's common stock to 16 new employees.The awards were made...",
    "url": "https://finnhub.io/api/news?id=717402d7c34b1957c2f22a315d55e56bd72e6047ffea3857e78659f14f9550db",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610290,
      "headline": "Incyte Reports Inducement Grants under Nasdaq Listing Rule 5635(4)",
      "id": 133122043,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "WILMINGTON - Incyte today announced that it granted restricted stock unit awards representing an aggregate of 13,351 shares of the Company's common stock to 16 new employees.The awards were made...",
      "url": "https://finnhub.io/api/news?id=717402d7c34b1957c2f22a315d55e56bd72e6047ffea3857e78659f14f9550db"
    }
  }
]